Search

Your search keyword '"O6-Methylguanine-DNA Methyltransferase"' showing total 1,103 results

Search Constraints

Start Over You searched for: Descriptor "O6-Methylguanine-DNA Methyltransferase" Remove constraint Descriptor: "O6-Methylguanine-DNA Methyltransferase"
1,103 results on '"O6-Methylguanine-DNA Methyltransferase"'

Search Results

1. Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma.

2. Prevalence of single-nucleotide variants in twenty-five pharmacogenes from a Cuban sample cohort.

3. MGMT methylation and its prognostic significance in inoperable IDH-wildtype glioblastoma: the MGMT-GBM study.

4. Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in MGMT-methylated glioblastoma.

5. MEN1 Deficiency‐Driven Activation of the β‐Catenin‐MGMT Axis Promotes Pancreatic Neuroendocrine Tumor Growth and Confers Temozolomide Resistance.

6. Studies on the role of moderate doses of ionizing radiation-induced cellular senescence in mouse lung tissue.

7. Cell cycle arrest combined with CDK1 inhibition suppresses genome-wide mutations by activating alternative DNA repair genes during genome editing.

8. Quality assessment of the MRI-radiomics studies for MGMT promoter methylation prediction in glioma: a systematic review and meta-analysis.

9. Naringin and temozolomide combination suppressed the growth of glioblastoma cells by promoting cell apoptosis: network pharmacology, in-vitro assays and metabolomics based study.

10. The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.

11. Nanoliposomes a future based delivery vehicle of cyanidin-3-O-glucoside against major chronic disease.

12. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas.

13. Unveiling the role of O(6)-methylguanine-DNA methyltransferase in cancer therapy: insights into alkylators, pharmacogenomics, and others.

14. Preoperative prediction of MGMT promoter methylation in glioblastoma based on multiregional and multi-sequence MRI radiomics analysis.

15. Prognostic Role of Platelet-to-Lymphocyte and Neutrophil-to-Lymphocyte Ratios in Patients Irradiated for Glioblastoma Multiforme.

16. Accurate and comprehensive evaluation of O6‐methylguanine‐DNA methyltransferase promoter methylation by nanopore sequencing.

17. Immune cell infiltration and inflammatory landscape in primary brain tumours.

18. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.

19. Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives.

20. Radiomics for predicting MGMT status in cerebral glioblastoma: comparison of different MRI sequences.

21. The power of integrating multiple data sources in medical imaging: A study of MGMT methylation status.

22. MGMT ProFWise: Unlocking a New Application for Combined Feature Selection and the Rank-Based Weighting Method to Link MGMT Methylation Status to Serum Protein Expression in Patients with Glioblastoma.

23. Gene Expression Patterns Associated with Survival in Glioblastoma.

24. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.

25. Genome‐wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non‐G‐CIMP glioblastomas with unmethylated MGMT promoter: MGMT‐dependent roles of GPR81.

26. Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma.

27. Imaging Role in Diagnosis, Prognosis, and Treatment Response Prediction Associated with High-grade Glioma.

28. Deep learning convolutional neural network ResNet101 and radiomic features accurately analyzes mpMRI imaging to predict MGMT promoter methylation status with transfer learning approach.

29. Identification of TMZ resistance‐associated histone post‐translational modifications in glioblastoma using multi‐omics data.

30. Unveiling the role of MGMT and DAPK hypermethylation in response to anti‐EGFR agents: Molecular insights for advancing HNSCC treatment.

31. MGMT unmethylation and high levels of CD47 and TIGIT indicate a poor prognosis in adult diffuse gliomas.

32. Computational pathology-based weakly supervised prediction model for MGMT promoter methylation status in glioblastoma.

33. Epigenetic modification and characterization of the MGMT promoter region using CRISPRoff in glioblastoma cells.

34. IDH1‐mutated Crohn's disease‐associated small bowel adenocarcinomas: Distinctive pathological features and association with MGMT methylation and serrated‐type dysplasia.

35. Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells.

36. Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O6‐methylguanine‐DNA methyltransferase gene in glioblastoma.

37. Assessing the Diagnostic Accuracy of Salivary Biomarkers in Detecting Oral Squamous Cell Carcinoma.

38. Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression.

39. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.

40. Novel MGMT inhibitors increase the sensitivity of glioma MGMT-positive cells to treatment with alkylating agents in vitro.

41. Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 Glioblastoma.

42. Development of A Radiomic Model for MGMT Promoter Methylation Detection in Glioblastoma Using Conventional MRI.

44. Effect of segmentation dimension on radiomics analysis for MGMT promoter methylation status in gliomas.

45. Predictive value of diffusion MRI-based parametric response mapping for prognosis and treatment response in glioblastoma.

46. Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach.

47. The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma.

48. Co-expression prognostic-related genes signature base on propofol and sevoflurane anesthesia predict prognosis and immunotherapy response in glioblastoma.

50. Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate.

Catalog

Books, media, physical & digital resources